Detalles de la búsqueda
1.
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.
J Magn Reson Imaging
; 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38294179
2.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat
; 199(3): 457-469, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061619
3.
Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.
Ann Surg Oncol
; 30(10): 6232-6240, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479842
4.
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 23(12): 1517-1524, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36306810
5.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Lancet Oncol
; 23(1): 149-160, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34902335
6.
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
J Magn Reson Imaging
; 56(6): 1901-1909, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35499264
7.
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
Cancer
; 127(16): 2880-2887, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878210
8.
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
Oncologist
; 26(2): e230-e240, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33140515
9.
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
Breast Cancer Res Treat
; 185(1): 1-12, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32920733
10.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
11.
The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.
Ann Surg Oncol
; 28(8): 4265-4274, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33403525
12.
Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer.
Ann Surg Oncol
; 28(13): 8610-8621, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34125346
13.
Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial.
J Natl Compr Canc Netw
; 20(3): 235-243, 2021 12 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965510
14.
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
Oncologist
; 25(9): 749-757, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32431013
15.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Oncologist
; 25(6): e909-e919, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32003919
16.
Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue.
Clin Chem
; 66(7): 934-945, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32613237
17.
Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
Breast J
; 26(8): 1572-1582, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32497289
18.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Breast Cancer Res
; 21(1): 78, 2019 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31277699
19.
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer
; 120(12): 1105-1112, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097774
20.
The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy.
Ann Surg
; 270(1): 147-157, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29489483